晚近性传播疾病(STD)的研究显示,沙眼衣原体所致的泌尿生殖道感染的发病率已超过淋病双球菌(淋菌)所致的感染。耐青霉素淋菌的日益增多,耐四环素沙眼衣原体的出现,近半数病因未明的非淋菌性尿道炎(NGU),以及尿道炎综合征和盆腔炎性疾病(PID)常系多种病原体混合感染,从而对临床治疗提出了新的挑战。1989年,美国疾病控制中心(CDC)推荐的STD的治疗方案中将第三代头孢菌素列为治疗淋病的首选药物。近年来,大量问世的氟喹诺酮类药物 Studies of late-stage STDs have shown that the incidence of genitourinary tract infections caused by Chlamydia trachomatis has surpassed that of gonorrhea. Increasing number of penicillin-resistant gonococcal bacteria, the emergence of tetracycline-resistant Chlamydia trachomatis, nearly half of the non-gonococcal urethritis of unknown etiology (NGU), and urethritis syndrome and pelvic inflammatory disease (PID) often mixed with multiple pathogens, thus The clinical treatment posed new challenges. In 1989, the third generation of cephalosporins was listed as the drug of choice for the treatment of gonorrhea in the treatment of STD recommended by the Centers for Disease Control and Prevention (CDC). In recent years, a large number of fluoroquinolones appear